We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 56

B.C. Court dismisses proposed class action against generic manufacturers of fentanyl patch

  • Stikeman Elliott LLP
  • -
  • Canada
  • -
  • July 8 2014

On June 20, 2014, Justice Bracken of the British Columbia Supreme Court dismissed a proposed class action against two generic manufacturers of

Supreme Court issues clear warning of need to respect the "patent bargain"

  • Stikeman Elliott LLP
  • -
  • Canada
  • -
  • November 12 2012

On Thursday, November 8, 2012, a unanimous Supreme Court of Canada issued a decision with significant implications for those wishing to obtain or enforce Canadian patent rights

Health Canada releases guidance on “danger to human health or safety” posed by consumer products

  • Stikeman Elliott LLP
  • -
  • Canada
  • -
  • December 20 2013

Health Canada has released a guidance document on factors it will consider when determining whether a consumer product poses a "danger to human

Bill C-17 (Vanessa’s Law) receives third reading

  • Stikeman Elliott LLP
  • -
  • Canada
  • -
  • October 24 2014

Bill C-17, An Act to Amend the Foods and Drugs Act (Vanessa's Law) has proceeded through the committee process without amendment and was read for a

Apotex denied damages for the delay it experienced in bringing its generic version of the medicine lovastatin to market

  • Stikeman Elliott LLP
  • -
  • Canada
  • -
  • February 7 2011

In a recent decision in Apotex Inc. v. Merck & Co., Inc., 2010 FC 1264, the Federal Court denied Apotex damages resulting from the delay it experienced in bringing its generic version of the drug lovastatin to market as a result of Merck’s prohibition application

Double patenting issue must be considered at time of hearing of application under the PM(NOC) regulations

  • Stikeman Elliott LLP
  • -
  • Canada
  • -
  • July 8 2010

The Federal Court of Appeal rendered a decision that will have important implications on the litigation strategy of pharmaceutical companies

Health Canada has released its statistical report for 2009 on the Patented Medicines (Notice of Compliance) Regulations and Data Protection provisions of the Food and Drug Regulations

  • Stikeman Elliott LLP
  • -
  • Canada
  • -
  • December 17 2010

Health Canada has released its statistical report for 2009 in respect of the administration of the Patented Medicines (Notice of Compliance) Regulations (the PM(NOC) Regulations) and data protection provisions of the Food and Drug Regulations

Apotex succeeds in getting a NOC despite itself

  • Stikeman Elliott LLP
  • -
  • Canada
  • -
  • December 1 2010

A recent Federal Court decision highlighted the differences in prohibition proceedings under the Patented Medicines (Notice of Compliance) Regulations (the NOC Regulations) and impeachment actions under the Patent Act

Federal Court of Appeal refuses a patent to a compound already the subject matter of product-by-process patent

  • Stikeman Elliott LLP
  • -
  • Canada
  • -
  • December 2 2010

On October 20, the Federal Court of Appeal put an end to the disparity in the jurisprudence surrounding whether a patentee could obtain a patent to a medicine subsequent to obtaining a patent to a process for producing the medicine by dismissing Bayer’s appeal in the case of Bayer Schering Pharma Aktiengesellschaft v. The Attorney General of Canada

Dedication of Merck patent insufficient to defeat allegation of double patenting

  • Stikeman Elliott LLP
  • -
  • Canada
  • -
  • December 1 2010

A recent decision of the Federal Court expounded on the harm that can occur if two patents issue for the same invention